Literature DB >> 12358558

Acne: effect of hormones on pathogenesis and management.

James C Shaw1.   

Abstract

In the pathogenesis of acne, androgen hormones play a crucial role. In the treatment of acne, hormonal therapies provide valuable alternatives to standard modalities in selected women. Although numerous factors contribute to the development of acne, the requirement for androgens is absolute and is one that allows for effective treatments in women through inhibition of androgen expression. The two prerequisites for androgen expression at the level of the pilosebaceous unit are the presence of androgen in the form of either testosterone or dihydrotestosterone; and functioning androgen receptors. A third component may be the metabolism of androgen precursors to active androgens within pilosebaceous units. Hormonal treatment of hyperandrogenism (acne, hirsutism, androgenetic alopecia) such as that seen in polycystic ovary syndrome, centers on reduction of circulating androgen levels and androgen receptor blockade. Combination oral contraceptives represent the primary treatment modality for reducing circulating androgens from ovarian and, to a lesser degree, adrenal sources. Newer formulations may also have clinically significant androgen receptor blocking and 5alpha-reductase inhibiting effects. Newer oral contraceptives have high safety profiles and are used widely internationally for this purpose. Androgen receptor blockers currently in use include spironolactone, cyproterone acetate, and flutamide. Androgen receptor blockers are frequently combined with oral contraceptives to achieve optimal results in selected women. In women with adrenal hyperplasia, low-dose corticosteroids may be added to reduce adrenal androgen precursors. Inhibition of enzymes of androgen metabolism in the pilosebaceous unit remain largely investigational in the treatment of acne, although the benefit of 5alpha-reductase (type 2) inhibition is established in androgenetic alopecia in men. This article reviews the essentials of hormonal influence in acne pathogenesis, discusses the hormonal therapies most utilized in the treatment of acne, and the pre-treatment evaluation of women in whom hormonal therapies are being considered.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12358558     DOI: 10.2165/00128071-200203080-00007

Source DB:  PubMed          Journal:  Am J Clin Dermatol        ISSN: 1175-0561            Impact factor:   7.403


  7 in total

1.  Hormonal treatment of acne in women.

Authors:  Tobechi L Ebede; Emily L Arch; Diane Berson
Journal:  J Clin Aesthet Dermatol       Date:  2009-12

Review 2.  Drospirenone/ethinylestradiol 3mg/20microg (24/4 day regimen): a review of its use in contraception, premenstrual dysphoric disorder and moderate acne vulgaris.

Authors:  Caroline Fenton; Keri Wellington; Marit D Moen; Dean M Robinson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

3.  Personality traits and common psychiatric conditions in adult patients with acne vulgaris.

Authors:  Ali İrfan Gül; Emine Çölgeçen
Journal:  Ann Dermatol       Date:  2015-02-03       Impact factor: 1.444

4.  Study of lipid profile in adult women with acne.

Authors:  Marisa Gonzaga da Cunha; Anna Luiza Fonseca Batista; Marzia Silva Macedo; Carlos D'Aparecida Santos Machado Filho; Fernando Luiz Affonso Fonseca
Journal:  Clin Cosmet Investig Dermatol       Date:  2015-08-17

Review 5.  Hormonal treatment of acne vulgaris: an update.

Authors:  Mohamed L Elsaie
Journal:  Clin Cosmet Investig Dermatol       Date:  2016-09-02

6.  Efficacy and safety of an oral contraceptive containing ethinylestradiol 20 µg/drospirenone 3 mg (24/4 regimen) in three indications in the People's Republic of China: a comparison with international studies.

Authors:  Joachim Marr; Zirong Huang; Baoxi Wang; Hongyan Zhang; Katrin Roth
Journal:  Open Access J Contracept       Date:  2015-07-10

7.  Spironolactone-Loaded LeciPlexes as Potential Topical Delivery Systems for Female Acne: In Vitro Appraisal and Ex Vivo Skin Permeability Studies.

Authors:  Ayman Salama; Mohamed Badran; Mohammed Elmowafy; Ghareb M Soliman
Journal:  Pharmaceutics       Date:  2019-12-25       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.